Study: Cholesterol Drug Only 2% Better Results than Placebo

Why should a 2% cardiovascular risk reduction in a drug that has shown nothing before this be considered a success? And, keep in mind, that this risk reduction did not include the most meaningful risk reduction–death. This study found no difference in the most important endpoints: overall deaths, cardiovascular deaths, or coronary deaths. Why does my profession accept this mediocrity? Not only do they accept it, they embrace it. It is pathetic. Folks, we spend too much money on drugs that provide little, if any, benefit. In fact, we spend more on drugs than any country on the face of the earth and we lag behind every major Western country on every important health and disease indicator. This study should be the last nail in the coffin for Vytorin. It is a failed drug that has little usefulness. We would be better served to remove it from the marketplace.